Study: FDA using postmarketing requirements for oncology drugs more often to assess dose optimization
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsProduct LifecycleUnited StatesRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsProduct LifecycleUnited States